H.7 Award Notice.docx

This is an Award Notice documenting the sole-source award of a Purchase Order to Psomagen, Inc. by the National Cancer Institute (NCI), a component of the Department of Health and Human Services National Institutes of Health. The award, issued on September 21, 2026, covers quality control of single cell samples, generation of sequencing libraries using 10X Chromium GEM-X Single Cell 5p RNA technology, and expression analysis data services for frozen clinical xenograft biosamples in ongoing NCI research studies. The Purchase Order (PO# 75N98026P01661) was awarded with a total value of $24,582.50 under the FAR 5.301(c) sole-source authority and carries the identifier PCA-NCI-09798. The award was made to Psomagen, Inc., located at 1330 Piccard Drive, Suite 103, Rockville, Maryland 20850-4372, based on their proprietary ownership and development of the required testing services and their existing integration with NCI's ongoing research data infrastructure.

The sole-source determination was justified by the critical constraint of maintaining consistency with prior data from ongoing research studies and the severe time-sensitivity of the biosamples, which have a maximum viability window of two hours transport time. Prior to award, the Government issued a Notice of Intent to Sole Source allowing interested vendors to submit capabilities statements demonstrating their ability to meet the requirement and integrate with existing Psomagen quality control, sequencing, and data analysis processes, though the Government retained sole discretion over the final competitive determination.